Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Protagonist Therapeutics Inc (PTGX)

Add PTGX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 9/22/2016 1:31:40 PM - Followers: 4 - Board type: Free - Posts Today: 0

Protagonist Therapeutics, Inc. (Protagonist) is a clinical-stage biopharmaceutical company. The Company has a technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Protagonist's primary focus is on developing oral peptide drugs that specifically target biological pathways. Its oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment. The Company's initial lead product candidates, PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease (IBD), a GI disease consisting primarily of ulcerative colitis (UC) and Crohn's disease (CD). Protagonist's product candidate beyond IBD is PTG-300, which is an injectable hepcidin mimetic peptide that the Company is developing for the treatment of iron overload disorders, such as transfusion-dependent b-Thalassemia, hereditary hemochromatosis (HH) and sickle cell disease (SCD).
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PTGX News: Current Report Filing (8-k) 12/14/2017 05:11:35 PM
PTGX News: Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors 12/14/2017 06:31:00 AM
PTGX News: Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 12/14/2017 06:30:00 AM
PTGX News: Protagonist Therapeutics to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference 12/04/2017 08:00:00 AM
PTGX News: Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200 11/09/2017 08:00:00 AM